Vera Therapeutics Inc Class A VERA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VERA is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $39.48
- Day Range
- $36.34–40.34
- 52-Week Range
- $6.07–50.78
- Bid/Ask
- $38.00 / $41.90
- Market Cap
- $2.07 Bil
- Volume/Avg
- 1.4 Mil / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 51
- Website
- https://www.veratx.com
Comparables
Valuation
Metric
|
VERA
|
VRDN
|
CELC
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 17.26 | 3.48 | 2.99 |
Price/Sales | — | 2,160.78 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
VERA
|
VRDN
|
CELC
|
---|---|---|---|
Quick Ratio | 7.21 | 17.93 | 12.78 |
Current Ratio | 7.71 | 18.26 | 13.43 |
Interest Coverage | −26.46 | −137.76 | −12.43 |
Quick Ratio
VERA
VRDN
CELC
Profitability
Metric
|
VERA
|
VRDN
|
CELC
|
---|---|---|---|
Return on Assets (Normalized) | −48.95% | −42.76% | −35.57% |
Return on Equity (Normalized) | −72.33% | −82.42% | −49.08% |
Return on Invested Capital (Normalized) | −58.12% | −50.70% | −39.21% |
Return on Assets
VERA
VRDN
CELC
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hhpkbvfp | Rmdz | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Cypppty | Flncnr | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lthxlkmqj | Qbjnb | $98.1 Bil | |
MRNA
| Moderna Inc | Kxfrtksr | Vklt | $39.1 Bil | |
ARGX
| argenx SE ADR | Vkgbxbm | Vtgd | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Ryrlldjl | Kcxr | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ffydfxhdc | Cmkllm | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zhmbkhx | Flwlms | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lfclkyyjw | Zbwfmf | $12.5 Bil | |
INCY
| Incyte Corp | Nghxpcf | Jyvsxtc | $11.9 Bil |